DIFFUSION PHARMACEUTICALS
Diffusion Pharmaceuticals Inc. is an innovative biopharmaceutical company developing novel therapies that enhance the body’s ability to deliver oxygen to the areas where it is needed most. Diffusion’s lead product candidate, TSC, is being developed to enhance the diffusion of oxygen to tissues with low oxygen levels, also known as hypoxia, a serious complication of many of medicine’s most intractable and difficult-to-treat conditions. In addition to TSC, Diffusion’s product candidate DFN-529, a novel PI3K/Akt/mTOR pathway inhibitor, is in early-stage development.
DIFFUSION PHARMACEUTICALS
Industry:
Biotechnology Health Care Therapeutics
Founded:
2001-01-01
Address:
Charlottesville, Virginia, United States
Country:
United States
Website Url:
http://www.diffusionpharma.com
Total Employee:
11+
Status:
Active
Contact:
4342200722
Total Funding:
119.48 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible Google Font API Google Analytics Apple Mobile Web Clips Icon Google Tag Manager WordPress Google Universal Analytics Apache Mobile Non Scaleable Content
Similar Organizations
Adamas Pharmaceuticals
Adamas Pharmaceuticals develops controlled release combination therapeutics for infectious diseases and central nervous system disorders.
Apellis Pharmaceuticals
Apellis Pharmaceuticals focuses on developing novel therapeutics and drug delivery technologies to address chronic inflammatory diseases.
Excision BioTherapeutics
Excision is developing CRISPR-based therapies to cure viral infectious diseases and improve the lives of chronically ill patients.
GIRx
GIRx is developing small molecule agents to treat diabetes, obesity and other metabolic conditions.
Milestone Pharmaceuticals
Milestone Pharmaceuticals is a drug development company developing small molecule therapeutics for the treatment of cardiovascular diseases.
Current Employees Featured
John L. Gainer Chief Scientific Officer &Co-founder @ Diffusion Pharmaceuticals
Chief Scientific Officer &Co-founder
Raven Jaeger Chief Regulatory Officer @ Diffusion Pharmaceuticals
Chief Regulatory Officer
2022-01-01
David R. Jones Chief Medical Officer @ Diffusion Pharmaceuticals
Chief Medical Officer
David G. Kalergis Co-Founder&Chief Executive Officer @ Diffusion Pharmaceuticals
Co-Founder&Chief Executive Officer
Ben Shealy Chief Financial Officer @ Diffusion Pharmaceuticals
Chief Financial Officer
Founder
Stock Details
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2015-12-28 | Stratus Media Group | Stratus Media Group acquired by Diffusion Pharmaceuticals | N/A |
Investors List
Jaffray Woodriff
Jaffray Woodriff investment in Convertible Note - Diffusion Pharmaceuticals
Jaffray Woodriff
Jaffray Woodriff investment in Debt Financing - Diffusion Pharmaceuticals
Jaffray Woodriff
Jaffray Woodriff investment in Debt Financing - Diffusion Pharmaceuticals
Office of Naval Research
Office of Naval Research investment in Grant - Diffusion Pharmaceuticals
U.S. Food and Drug Administration
U.S. Food and Drug Administration investment in Private Equity Round - Diffusion Pharmaceuticals
Third Security
Third Security investment in Grant - Diffusion Pharmaceuticals
Office of Naval Research
Office of Naval Research investment in Grant - Diffusion Pharmaceuticals
Key Employee Changes
| Date | New article |
|---|---|
| 2022-05-18 | Diffusion Pharmaceuticals Announces Appointment of Raven Jaeger, M.S., as Chief Regulatory Officer |
Official Site Inspections
http://www.diffusionpharma.com
- Host name: aec037177372cc6cd.awsglobalaccelerator.com
- IP address: 3.33.251.168
- Location: Seattle United States
- Latitude: 47.6348
- Longitude: -122.3451
- Metro Code: 819
- Timezone: America/Los_Angeles
- Postal: 98109
More informations about "Diffusion Pharmaceuticals"
Diffusion Pharmaceuticals - Crunchbase Company Profile & Funding
Contact Email info@diffusionpharma.com Phone Number 4342200722 Diffusion Pharmaceuticals Inc. is an innovative biopharmaceutical company developing novel therapies that enhance the …See details»
Diffusion Pharmaceuticals - Org Chart, Teams, Culture & Jobs
View Diffusion Pharmaceuticals' up-to-date org chart, open roles, and culture details. Find executives, board members, teams, related companies, and more.See details»
Diffusion Pharmaceuticals Sends Letter to Stockholders …
Dec 5, 2022 The Company’s proxy statement and other important information related to the Annual Meeting can be found at investors.diffusionpharma.com The full text of the letter …See details»
CervoMed Company Profile - Office Locations, Competitors ... - Craft
Oct 29, 2024 CervoMed has 4 employees at their 1 location and $7.14 m in annual revenue in FY 2023. See insights on CervoMed including office locations, competitors, revenue, …See details»
Diffusion Pharmaceuticals
Feb 25, 2025 Diffusion Pharmaceuticals was founded in 2003 as a biotechnology spinoff of the University of Virginia. The company has developed a portfolio of drugs that focus on improving …See details»
Diffusion Pharmaceuticals Stockholders Approve Merger with
Aug 15, 2023 Approximately 71% of Stockholders Voted in Favor of the Transaction Diffusion Announces 1-for-1.5 Reverse Stock Split Merger on Track to Close on August 16, 2023See details»
Company Diffusion Pharmaceuticals Inc OTC Bulletin Board
Diffusion Pharmaceuticals, Inc. 300 East Main Street Suite 201. 22902-8759, Charlottesville +434 220 0718. http://www.diffusionpharma.comSee details»
Nextsource | Company Profile | Diffusion Pharmaceuticals
Explore the company profile of Diffusion Pharmaceuticals (diffusionpharma.com) featuring business details and insights, funding data, industry info, employee numbers, and more.See details»
Diffusion Pharmaceuticals - VentureRadar
Website: http://www.diffusionpharma.com. Develops novel therapies to enhance oxygen delivery in the body, targeting hypoxia-related conditions such as COVID-19 ...See details»
Diffusion Pharmaceuticals - News, Mergers and Acquisitions, …
Usearch identified 2 signals for Diffusion Pharmaceuticals, including: 2 Mergers and Acquisitions. Usearch discovered 1 location for Diffusion Pharmaceuticals including locations in …See details»
EIP Pharma and Diffusion Pharmaceuticals Announce Merger …
Mar 30, 2023 Combined company will pursue late-stage clinical development of oral neflamapimod for the treatment of dementia with Lewy bodies EIP Pharma to initiate in 2Q …See details»
Diffusion Pharmaceuticals Issues Letter to Shareholders
Sep 9, 2021 The first episode of this podcast series, entitled “The Science of Solving for Hypoxia” is available through the Diffusion website at www.diffusionpharma.com. 1. …See details»
Diffusion Pharmaceuticals Stockholders Approve Merger with EIP …
Aug 15, 2023 Approximately 71% of Stockholders Voted in Favor of the TransactionDiffusion Announces 1-for-1.5 Reverse Stock SplitMerger on Track to Close on August 16, 2023 …See details»
Diffusion Pharmaceuticals - Products, Competitors, Financials ...
Investors and stockholders may obtain a copy of the definitive Proxy Statement and other relevant documents filed by Diffusion with the SEC free of charge from the SEC’s website, …See details»
Diffusion Pharmaceuticals Announces Strategic Review
Oct 25, 2022 Diffusion Pharmaceuticals Announces Strategic Review Process to Evaluate Value-Enhancing Alternatives including Opportunities to Better Leverage TSCSee details»
Diffusion Pharmaceuticals - PitchBook
Diffusion Pharmaceuticals General Information Description. CervoMed Inc is a clinical-stage biotechnology company. It is focused on developing treatments for age-related neurologic …See details»
Diffusion Pharmaceuticals Inc. | Diffusion Pharmaceuticals …
• Program to focus on enhanced blood oxygenation and reduction in patient progression to Intensive Care Units • Patient enrollment planned for both the U.S. and Eastern Europe …See details»
Simplification for success: Rewiring the biopharma operating model
Mar 21, 2025 Thirty-seven of them expect their organization to pursue a simplification effort over the next 12 months. Thirty-two respondents say they believe they need a significantly different …See details»
Diffusion Pharmaceuticals Sees Significant Progress in its Strategic ...
Nov 14, 2022 Diffusion Pharmaceuticals Inc. Diffusion in Active Bidding Stage and Encouraged by Response to the Strategic Review Process. Diffusion Board of Directors Rejects Woefully …See details»
Diffusion Pharmaceuticals Reports Third Quarter 2022
Nov 14, 2022 September 30, 2022 December 31, 2021: Assets Current assets: Cash and cash equivalents $ 6,587,018 $ 37,313,558 Marketable securitiesSee details»